Recent advances toward the clinical application of PTH (1-34) in fracture healing.
PTH 1-34, an active form of parathyroid hormone, has been shown to enhance osteoblastic bone formation when administered as a daily subcutaneous injection. The effect of the intermittent administration of PTH (1-34) is an uncoupling of bone turnover with an increase in bone mass and density and decrease in risk of vertebral and nonvertebral fractures. While PTH (1-34) has been used clinically to increase bone mass and reduce fracture risk in postmenopausal women with osteoporosis, there is increasing evidence that PTH (1-34) may promote fracture healing. Animal studies have demonstrated accelerated callus formation with enhanced remodeling and biomechanical properties of the healing fracture. Given these effects, PTH (1-34) will likely be used clinically to enhance fracture union in poor healing situations such as osteoporosis and recalcitrant nonunions.
Cipriano
Cara A
CA
University of Pennsylvania School of Medicine, Philadelphia, PA, USA.
Issack
Paul S
PS
Shindle
Lisa
L
Werner
Clément M L
CM
Helfet
David L
DL
Lane
Joseph M
JM